What Next for ANTIBE THERAPEUTICS INC ORDINARY SHARES (OTCMKTS:ATBPF) Stock After Decrease in Shorted Shares?

June 19, 2018 - By Dolores Ford

Antibe Therapeutics Inc. (OTCMKTS:ATBPF) Logo

The stock of ANTIBE THERAPEUTICS INC ORDINARY SHARES (OTCMKTS:ATBPF) registered a decrease of 49.62% in short interest. ATBPF’s total short interest was 53,100 shares in June as published by FINRA. Its down 49.62% from 105,400 shares, reported previously. With 138,100 shares average volume, it will take short sellers 0 days to cover their ATBPF’s short positions.

The stock 0.16% or $0 during the last trading session, reaching $0.302. It is down 0.00% since June 19, 2017 and is . It has underperformed by 12.57% the S&P500.

Antibe Therapeutics Inc., together with its subsidiaries, originates, develops, and out-licenses patent protected pharmaceuticals primarily in Canada, Europe, and the United States. The company has market cap of $63.47 million. The company's lead compound is the ATB-346, a hydrogen sulfide-releasing derivative of naproxen that is in Phase II clinical study for the treatment of osteoarthritis, as well as to treat rheumatoid arthritis, ankylosing spondylitis, and general pain reduction. It currently has negative earnings. The Company’s products also comprise ATB-352, which is in preclinical stage for the treatment of gout, dental pain, post-surgical pain, etc.; and ATB-340 that is in preclinical development stage for the treatment of cardiovascular disease and cancer chemoprevention.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: